| Drug Name |
Palivizumab |
| Drug ID |
BADD_D01658 |
| Description |
Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0). Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF) |
| Indications and Usage |
For prophylaxis of respiratory diseases casued by respiratory syncytial virus. |
| Marketing Status |
approved; investigational |
| ATC Code |
J06BD01 |
| DrugBank ID |
DB00110
|
| KEGG ID |
D02737
|
| MeSH ID |
D000069455
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0A1AS
|
| NDC Product Code |
66658-230; 0310-4113; 66658-231 |
| UNII |
DQ448MW7KS
|
| Synonyms |
Palivizumab | MEDI 493 | Monoclonal Antibody MEDI-493 | Monoclonal Antibody MEDI 493 | Monoclonal Antibody MEDI493 | MEDI-493 | MEDI493 | Synagis |
